Showing 1051-1060 of 7667 results for "".
- Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officerhttps://practicaldermatology.com/news/trevi-therapeutics-appoints-yann-mazabraud-as-chief-commercial-officer/2457685/Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations. Trevi is a late-stage biopharmaceutical com…
- AMSPA Merges with IALAhttps://practicaldermatology.com/news/amspa-merges-with-iala/2457688/The American Med Spa Association (AmSpa) is merging with the International Aesthetic and Laser Association, Inc. (IALA). The merger will add more than 250 members to AmSpa’s 1,200-plus existing members. IALA’s membership will transition to the AmSpa group over the next month and will receive be…
- New From InMode: Triton Multi-Wavelength Hair Removal Laserhttps://practicaldermatology.com/news/new-from-inmode-triton-multi-wavelength-hair-removal-laser/2457698/InMode Ltd. is launching the Triton hair removal device. Recently cleared by the FDA, Triton is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode, and Nd:YAG wavelengths. The company says Triton’s sim…
- Dermtech's Noninvasive Melanoma Screen Improves Care, Lowers Costhttps://practicaldermatology.com/news/dermtechs-noninvasive-melanoma-screen-improves-care-lowers-cost/2457700/New research shows that DermTech’s Pigmented Lesion Assay (PLA) reduces cost while improving the care of patients with primary pigmented skin lesions suggestive of melanoma. The research appears in JAMA Dermatology. The purpose of the study was to assess the cost implications of using the pigmente…
- About 415 Million People May Have Rosacea Worldwidehttps://practicaldermatology.com/news/about-415-million-people-may-have-rosacea-worldwide/2457701/As many as 415 million people worldwide may have rosacea, according to new research in the British Journal of Dermatology. Dr. Jacob Thyssen and colleagues at the University of Copenhagen, Denmark, conducted a systematic review of population-based studies that included information on the incidence…
- Nanotechnology May Improve Onychomycosis, Cut Costshttps://practicaldermatology.com/news/nanotechnology-may-improve-onychomycosis-cut-costs/2457702/Nanotechnology can improve efinaconazole treatment for onychomycosis and make it more cost effective, according to new research in the Journal of Drugs in Dermatology. Adam Friedman, MD, professor of dermatology at the George Washington University School of Medicine and Health Sciences in Washingt…
- Life Sciences Industry Eyes $1.5 Trillion Milestonehttps://practicaldermatology.com/news/life-sciences-industry-eyes-15-trillion-milestone/2457703/The life sciences industry is nearing a $1.5 trillion milestone, according to an analysis from Frost & Sullivan. The firm’s Global Life Sciences Industry Outlook, 2018 report finds that healthcare digitization and consumerization, the explosion of patient data, and the emergence of value-based reim…
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying…
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully with liposuction, patients must wait a few months before treatment, according to…
- FDA Approves Braftovi in Combination with Mektovi for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-approves-of-braftovi-in-combination-with-mektovi-for-advanced-braf-mutant-melanoma/2457710/The FDA has approved Array BioPharma Inc.'s BRAFTOVI (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated…